Figure 4.
Results (in percentage) of different screening steps according to final patients' classification. *Statistical significance <0.025 for post-hoc analysis. MSA/MAA, myositis specific antibodies/myositis associated antibodies; RF, rheumatoid factor; anti-CPP, anti-cyclic citrullinated peptide antibodies; NVC, nailfold videocapillaroscopy.
